Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 386-391

  Nesheim, Michael ^a   Wang, Wei ^b   Boffa, Michael ^b   Nagashima, Mariko ^b   Morser, John ^b   Bajzar, Laszlo ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CARBOXYPEPTIDASE B; PLASMA PROTEIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BLOOD CLOTTING; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME ISOLATION; ENZYME STRUCTURE; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 0030742896     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657557     Document Type: Conference Paper

References (50)

1. Stenflo JA New vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem 1976; 251:355-63.
2. Kisiel W. Human Plasma Protein C Isolation, Characterization, and Mechanism of Activation by Alpha-Thrombin. J Clin Invest 1979;64:761-769.
3. Kisiel W, Ericsson LH, Davie EW. Proteolytic activation of protein C from bovine plasma. Biochemistry 1976; 15:4893-4900.
4. Nesheim ME, Canfield WM, Kisiel W, Mann KG. Modulation of prothrombinase activity through inactivation of factor Va by protein Ca. Blood 1979; 54:293.
5. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979; 71: 333-42.
6. Vehar GA, Davie EW. Preparation and properties of bovine factor VIII. Biochemistry 1980;19:401-9.
7. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78:2249-52.
8. Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombin catalyzed activation of protein C. J Biol Chem 1981; 256:5532-35.
9. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257:859-64.
10. Jackman RW, Beeler DL, Van De Water L, Rosenberg RD. Characterization of a thrombomodulin cDNA reveals structural similarity to the low density lipoprotein receptor. Proc Natl Acad Sci USA 1986; 83:8834-38.
11. Wen D, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE. Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochemistry 1987; 26: 4350-57.
12. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6:1891-7.
13. Jackman RW, Beeler DL, Fritze L, Soff G, Rosenberg RD. Human thrombomodulin gene is intron depleted: Nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. Proc Natl Acad Sci USA 1987; 84:6425-9.
14. Sadler JE, Lentz SR, Sheehan JP, Tsiang M, Wu Q. Structure-function relationships of the thrombin-thrombomodulin interaction. Haemost 1993; 23:183-93.
15. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9:946-55.
16. Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70:29-35.
17. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995; 92:850-4.
18. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-84.
19. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271:16603-8.
20. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991;269:21833-8.
21. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
22. Taylor FB, Carroll RC, Gerrard J, Esmon CT, Radcliffe RD. Lysis of clots prepared from whole blood and plasma. FASEB J 1981; 40:2092-8.
23. Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 1221-8.
24. Taylor FB, Lockhart MS. A new function for activated protein C: activated protein C prevents inhibition of plasminogen activators by releasate from mononuclear leukocytes - platelet suspensions stimulated by phorbol diester. Thromb Res 1985; 37:155-64.
25. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68:1218-23.
26. de Fouw NJ, Haverkate F, Bertina RM, Koopman J, van Wijngaarden A, van Hinsbergh VWM. The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. Blood 1986; 67:1189-92.
27. Burdick MD, Schaub RG. Human protein C induces anticoagulation and increased fibrinolytic activity in the cat. Thromb Res 1987; 45:413-9.
28. de Fouw NJ, Bertina RM, Haverkate F. Stimulation of fibrinolysis by activated protein C (APC). Thromb Haemost 1987; 58:48.
29. de Fouw NJ, de Jong YF, Haverkate F, Bertina RM. The influence of thrombin and platelets on fibrin clot lysis rates in vitro: A study using a clot lysis system consisting of purified human proteins. Fibrinolysis 1988; 2:235-44.
30. de Fouw NJ, Haverkate F, Bertina RM. Protein C and fibrinolysis: A link between coagulation and fibrinolysis. Adv Exp Med Biol 1990; 281:235-43.
31. Bajzar L, Fredenburgh JC, Nesheim ME. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 1990; 265: 16948-54.
32. Bajzar L, Nesheim M. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993; 268: 8608-16.
33. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269:15937-44.
34. Bajzar L, Nesheim M, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of TAFI. Blood, submitted for publication.
35. Cote HCF, Stevens WK, Bajzar L, Banfield DK, Nesheim ME, MacGillivray RTA. Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A). J Biol Chem 1994; 269:11374-80.
36. Cote HCF, Bajzar L, Stevens WK, Samis J, Morser J, MacGillivray RTA, Nesheim ME. Functional characterization of recombinant human meizothrombin and meizothrombin(desF1). J Biol Chem 1997; in press.
37. Wang W, Boffa MB, Walker J, Nesheim ME. A study of the mechanism of inhibition of tPA-mediated fibrinolysis by activated TAFI. Fibrinolysis 1996; 10:278:82 (abstract).
38. Stearns DJ, Kurosawa S, Esmon CT. Microthrombomodulin. Residues 310-486 from the epidermal growth factor precursor homology domain of thrombomodulin will accelerate protein C activation. J Biol Chem 1989; 264:3352-6.
39. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 264:10351-3.
40. Hayashi T, Zushi M, Yamamoto S, Suzuki K. Further localization of binding sites for thrombin and protein C in human thrombomodulin. J Biol Chem 1990; 265:20156-9.
41. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 1992; 267:6164-70.
42. Parkinson JF, Nagashima M, Kuhn I, Leonard J, Morser J. Structure-function studies of the epidermal growth factor domains of human thrombomodulin. Biochem Biophys Res Commun 1992; 185:567-76.
43. Nagashima M, Lundh E, Leonard JC, Morser J, Parkinson JF. Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity. J Biol Chem 1993; 268:2888-92.
44. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews WH, Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 1992; 90: 2565-73.
45. Clarke JH, Light DR, Blasko E, Parkinson JF, Nagashima M, McLean K, Vilander L, Andrews WH, Morser J, Glaser CB. The short loop between epidermal growth factor-like domains 4 and 5 is critical for human thrombomodulin function. J Biol Chem 1993; 268:6309-15.
46. Lee CD, Mann KG. Activation/anactivation of human factor V by plasmin. Blood 1989; 73:185-90.
47. Giles AR, Nesheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 1990; 63(3):476-81.
48. Broze G Jr., Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88:3815-23.
49. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93:1328-30.
50. Skidgel RA. Basic carboxypeptidases: Regulators of peptide hormone activity. Trends Pharmacol Sci 1988; 9:299-304.